businesspress24.com - SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharma
 

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX

ID: 1313062

(firmenpresse) - NEW YORK, NY -- (Marketwired) -- 10/27/14 -- Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Pacira Pharmaceuticals, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) stock between April 9, 2012 and September 24, 2014.

For more information, click here: .

The complaint alleges that the Company misstated and/or failed to disclose that it: (a) overstated the efficacy of its product EXPAREL; (b) improperly promoted EXPAREL as able to work for up to 72 hours despite it being only approved for 24-hour pain relief; (c) improperly claimed EXPAREL as safe and effective for use in cholecystectomy and colectomy, though its approved labeling does not provide for such use; and (d) derives a substantial portion of its revenues from off-label marketing.

On September 25, 2014, the Company revealed it had received a Warning Letter from the FDA regarding the marketing of EXPAREL. Shares of Pacira closed at $106.28 per share the day before the announcement, and recently closed at just $98.35 per share on October 6, 2014.

If you suffered a loss in Pacira you have until December 2, 2014 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn''t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit .

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm''s 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.







CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (866) 367-6510


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against EveryWare Global, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 8, 2014 -- EVRY
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Retrophin, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 19, 2014 -- RTRX
Bereitgestellt von Benutzer: Marketwired
Datum: 27.10.2014 - 15:36 Uhr
Sprache: Deutsch
News-ID 1313062
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

NEW YORK, NY


Phone:

Kategorie:

Legal


Anmerkungen:


Diese Pressemitteilung wurde bisher 260 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Pacira Pharmaceuticals, Inc. and Its Board of Directors and a Lead Plaintiff Deadline of December 2, 2014 -- PCRX
"
steht unter der journalistisch-redaktionellen Verantwortung von

Levi & Korsinsky, LLP (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Levi & Korsinsky, LLP



 

Who is online

All members: 10 572
Register today: 2
Register yesterday: 0
Members online: 0
Guests online: 124


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.